183 related articles for article (PubMed ID: 23908358)
1. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.
Gagné V; Rousseau J; Labuda M; Sharif-Askari B; Brukner I; Laverdière C; Ceppi F; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Krajinovic M
Clin Cancer Res; 2013 Sep; 19(18):5240-9. PubMed ID: 23908358
[TBL] [Abstract][Full Text] [Related]
2. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
[TBL] [Abstract][Full Text] [Related]
3. Multi-agent chemotherapy overcomes glucocorticoid resistance conferred by a BIM deletion polymorphism in pediatric acute lymphoblastic leukemia.
Soh SX; Lim JY; Huang JW; Jiang N; Yeoh AE; Ong ST
PLoS One; 2014; 9(8):e103435. PubMed ID: 25090024
[TBL] [Abstract][Full Text] [Related]
4. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP; Hillmer AM; Chuah CT; Juan WC; Ko TK; Teo AS; Ariyaratne PN; Takahashi N; Sawada K; Fei Y; Soh S; Lee WH; Huang JW; Allen JC; Woo XY; Nagarajan N; Kumar V; Thalamuthu A; Poh WT; Ang AL; Mya HT; How GF; Yang LY; Koh LP; Chowbay B; Chang CT; Nadarajan VS; Chng WJ; Than H; Lim LC; Goh YT; Zhang S; Poh D; Tan P; Seet JE; Ang MK; Chau NM; Ng QS; Tan DS; Soda M; Isobe K; Nöthen MM; Wong TY; Shahab A; Ruan X; Cacheux-Rataboul V; Sung WK; Tan EH; Yatabe Y; Mano H; Soo RA; Chin TM; Lim WT; Ruan Y; Ong ST
Nat Med; 2012 Mar; 18(4):521-8. PubMed ID: 22426421
[TBL] [Abstract][Full Text] [Related]
5. Expression and glucocorticoid-regulation of "Bam", a novel BH3-only transcript in acute lymphoblastic leukemia.
Mansha M; Wasim M; Kofler A; Ploner C
Mol Biol Rep; 2012 May; 39(5):6007-13. PubMed ID: 22237863
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
8. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
9. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Nakagawa T; Takeuchi S; Yamada T; Ebi H; Sano T; Nanjo S; Ishikawa D; Sato M; Hasegawa Y; Sekido Y; Yano S
Cancer Res; 2013 Apr; 73(8):2428-34. PubMed ID: 23382048
[TBL] [Abstract][Full Text] [Related]
10. Pro-apoptotic protein BIM in apoptosis of glucocorticoid-sensitive and -resistant acute lymphoblastic leukemia CEM cells.
Zhao YN; Guo X; Ma ZG; Gu L; Ge J; Li Q
Med Oncol; 2011 Dec; 28(4):1609-17. PubMed ID: 20697841
[TBL] [Abstract][Full Text] [Related]
11. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner.
Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM
J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306
[TBL] [Abstract][Full Text] [Related]
12. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia.
Jiang N; Koh GS; Lim JY; Kham SK; Ariffin H; Chew FT; Yeoh AE
Exp Hematol; 2011 Mar; 39(3):321-9, 329.e1-3. PubMed ID: 21130142
[TBL] [Abstract][Full Text] [Related]
13. 2-deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines.
Zagorodna O; Martin SM; Rutkowski DT; Kuwana T; Spitz DR; Knudson CM
Oncogene; 2012 May; 31(22):2738-49. PubMed ID: 21986940
[TBL] [Abstract][Full Text] [Related]
14. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
Shukla S; Rizvi F; Raisuddin S; Kakkar P
Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
[TBL] [Abstract][Full Text] [Related]
15. TGFbeta-mediated apoptosis of Burkitt's lymphoma BL41 cells is associated with the relocation of mitochondrial BimEL.
Clybouw C; Mchichi BE; Hadji A; Portier A; Auffredou MT; Arnoult D; Leca G; Vazquez A
Oncogene; 2008 May; 27(24):3446-56. PubMed ID: 18193085
[TBL] [Abstract][Full Text] [Related]
16. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
Rambal AA; Panaguiton ZL; Kramer L; Grant S; Harada H
Leukemia; 2009 Oct; 23(10):1744-54. PubMed ID: 19404317
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor.
Bachmann PS; Gorman R; Mackenzie KL; Lutze-Mann L; Lock RB
Blood; 2005 Mar; 105(6):2519-26. PubMed ID: 15572593
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
[TBL] [Abstract][Full Text] [Related]
20. Prevention of cytokine withdrawal-induced apoptosis by Mcl-1 requires interaction between Mcl-1 and Bim.
Jamil S; Wang SW; Bondy L; Mojtabavi S; Duronio V
Biochem Cell Biol; 2010 Oct; 88(5):809-18. PubMed ID: 20921992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
